Originally published by our sister publication Pain Medicine News
The FDA approved a second non prescription naloxone hydrochloride 3-mg nasal spray (RiVive, Harm Reduction Therapeutics) for the emergency treatment of known or suspected opioid overdose.
The approval of RiVive nasal spray for nonprescription use was supported by data from a study submitted by the manufacturer that showed similar levels of RiVive reach the bloodstream as an approved prescription naloxone product. The drug